| Zhao, Dan |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor |
|
|
| Recruiting | 1/2 | 100 | US | AFNT-211 | Affini-T Therapeutics, Inc. | Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V | 12/25 | 12/29 | | |
PERIO-03, NCT05607953: Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1 | 60 | US | SD-101, anti-PD-1 | TriSalus Life Sciences, Inc. | Locally Advanced Pancreatic Adenocarcinoma | 10/24 | 10/26 | | |
NCT05634525: Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients |
|
|
| Recruiting | 1 | 14 | US | MRTX849, Adagrasib | M.D. Anderson Cancer Center, Mirati Therapeutics Inc. | Metastatic Pancreatic Cancer | 11/27 | 11/27 | | |
| Cui, Dongfeng |
| No trials found |
